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Coagulation factor XIII (FXIII) is activated in the last stage of
the coagulation cascade in the presence of thrombin and
Ca2þ by cleavage and release of the activation peptide (FXIII
activation peptide, AP-FXIII) from the A-subunit and disso-
ciation of the carrier B-subunits. Activated FXIII then cross-
links ﬁbrin ﬁbers and incorporates antiﬁbrinolytic proteins
into the clot. Therefore, FXIII has a crucial role in stabilizing
ﬁbrin: it determines clot properties and ﬁbrinolysis, and
contributes to clot formation in every acute thrombotic
event.1 Consequently, FXIII is consumed during acute throm-
botic events leading to a reduction in systemic circulating
FXIII plasma levels which are also associated with outcome,
e.g., in acute myocardial infarction,2 stroke,3–5 and venous
thromboembolism.6–9 In patients with acute stroke, we
could detect circulating free AP-FXIII for the ﬁrst time and
prove its release during an acute thrombotic event.4,10
Cerebral venous thrombosis (CVT) is an unusual manifesta-
tion of venous thrombosis with a high incidence in young
adults.11 Prognosis of this potentially life-threatening condi-
tiondepends on rapiddiagnosis and treatment, but differential
diagnosis can be challenging due to a variable clinical presen-
tation andunspeciﬁc symptoms suchasheadache.11Therefore,
combinations of laboratory parameters such as D-dimer levels
andclinical probabilityscoresmaybehelpful in thediagnosisof
CVT.12
FXIII has never been analyzed in patients with CVT. The
aim of the present study was therefore twofold: (1) measure
plasma levels of FXIII-A antigen and AP-FXIII in patients with
suspected CVT for the ﬁrst time and compare FXIII levels
between patients with conﬁrmed and excluded CVT. (2)
Investigate if FXIII levels could help to distinguish between
patients with/without CVT and improve diagnosis of CVT.
Patients with clinical possibility of CVT were recruited at
the University Hospitals of Bern and Amsterdam between
2009 and 2016. Adult patients, aged 18 to 85 years, were
included if oneor several of the following symptomsor clinical
ﬁndingsof less than30-daydurationwerepresent: (1) isolated
unexpected headache; (2) headache associated with focal
neurological deﬁcits; (3) headache associated with disturbed
consciousness; (4) headache associated with seizure(s); (5)
unexplained papilloedema. We excluded patients with (1)
anticoagulation treatment prior to admission, (2) one of the
following diseases 3 months prior to admission: deep vein
thrombosis, pulmonary embolism, ischemic stroke, myocar-
dial infarction, and other vascular disease. Pregnant patients
were also excluded from analysis. All patients gave informed
consent to the protocol approved by the respective local ethics
committee. On admission, patients underwent neurological
examination, magnetic resonance (MR)- and/or computed
tomography (CT)-venography, androutinelaboratoryanalysis.
Citratedplasmasampleswere collecteduponadmissionand
stored frozen until laboratory analysis. FXIII A-subunit antigen
(expressed as percentage relative to a normal standard plasma)
and AP-FXIII levelsweremeasured by in-house enzyme-linked
immunosorbent assay (ELISA) methods described earlier.10,13
D-dimer levels were determined with an automated immu-
noenzymatic assay (VIDAS D-Dimer Exclusion II, BioMérieux).
Statistical analyseswereperformedwith IBMSPSSStatistics
(version 24.0) software (SPSS, Chicago, IL, United States).
Continuous variables were tested for normal distribution
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with the Kolmogorov–Smirnov test and compared between
groups using the t-test (normally distributed data) or Mann–
Whitney U-test. Correlations between variables were evaluat-
edwith the Pearson (normally distributed data) or Spearman’s
Rho correlation coefﬁcients. Distributions of frequencies were
compared with the Chi-square test. A univariate general linear
model was used to adjust for possible confounders.
In total, 344 consecutive patients with suspected CVTwere
included (189 in Bern, 155 in Amsterdam). In 94 patients, CVT
was conﬁrmed by imaging. In 31 patients, other vascular
diseases were diagnosed, namely intracerebral hemorrhage
(n ¼ 12), subdural hemorrhage (n ¼ 2), subarachnoidal hem-
orrhage (n ¼ 3), ischemic stroke or transient ischemic attack
(n ¼ 9), vessel dissection (n ¼ 2), arteriovenous malformation
(n ¼ 1), pituitary apoplexy (n ¼ 1), and vena ophthalmica
thrombosis (n ¼ 1). The remaining 219 patients had no CVT
and no other vascular diseases, and the most frequent diagno-
ses includedmigraine (n ¼ 57),unspeciﬁedheadache(n ¼ 51),
tension headache (n ¼ 28), systemic infection (n ¼ 14),
meningitis (n ¼ 12), and epilepsy (n ¼ 10). Characteristics of
the CVT patients and all the non-CVT patients taken together
are summarized in ►Table 1. Nine patients had hemostasis
disorders including FV Leiden (3 patients), positive lupus
anticoagulant (1), antiphospholipid syndrome (1), protein C
deﬁciency (1), essential thrombocythemia (2), plateletdysfunc-
tion (1), and unspeciﬁed thrombotic diathesis with recurrent
venous thrombotic events.
FXIII-A antigen levels were signiﬁcantly lower in CVT
patients compared with patients in whom CVTwas excluded
(►Table 1). However, FXIII-A levels in CVT patients were still
within the normal range of 70 to 140% and therefore not
deemedsuitable asamarker fordiagnosis ofCVT.Therewasno
difference in AP-FXIII levels between CVT and non-CVT
patients, but in the CVT group, AP-FXIII levels were inversely
correlatedwith thedurationof symptoms(0.262,p ¼ 0.011).
We also analyzed FXIII and D-dimer levels separately in the
patients with other vascular diseases (►Table 2). While
D-dimer levels signiﬁcantly differed between all three groups,
only FXIII-A antigen levels remained signiﬁcantly different
between CVT patients and patients with no CVT and no other
vasculardiseases. Since FXIII-A antigen levels, but not AP-FXIII,
showedweak but statistically signiﬁcant correlationswith age
(correlation coefﬁcient: 0.129, p ¼ 0.017) and body mass
index (correlation coefﬁcient: 0.113, p ¼ 0.044), we used a
univariate general linear model to adjust for these possible
confounders. However, after adjustment, the difference in
FXIII-A antigen levels between CVT and non-CVT patients still
remained statistically signiﬁcant.
When CVT patients were grouped according to symptom
duration into acute (symptomonset < 48 hours, n ¼ 11), sub-
acute (symptomonset 48 hours to 7 days, n ¼ 47), and chronic
(symptom onset>7 days, n ¼ 35), FXIII-A levels were lower in
acute than in subacute and chronic CVT patients (82.8%
[standard deviation, SD: 31.3] vs. 95.1% [SD: 27.9] vs. 94.5%
[SD 27.0]) and AP-FXIII levels were higher in acute than in
subacute and chronic CVT patients (7.2 ng/mL [SD: 5.7] vs.
4.7 ng/mL [SD: 3.1] vs. 4.7 ng/mL [SD: 3.6]), but the differences
were not statistically signiﬁcant. FXIII-A antigen, but not
AP-FXIII levels, showed a statistically signiﬁcant positive corre-
lation with Glasgow Coma Scale (GCS) on admission (0.152,
p ¼ 0.004). Patients with GCS < 9 had signiﬁcantly lower
FXIII-A levels (mean: 79.1%; SD: 24.4) compared with patients
with GCS 9 (102.8%, SD: 28.2), p ¼ 0.012, whereas AP-FXIII
levels did not differ.
For the ﬁrst time we have measured FXIII-A and AP-FXIII
levels in consecutive patients with suspected CVT in whom
the diagnosis of CVTwas either conﬁrmed or excluded. FXIII-
A antigen levels were signiﬁcantly lower in CVT patients
compared with non-CVT patients. This ﬁnding can be
explained by activation and consumption of FXIII and is
consistent with observations in other patients with acute
thrombotic events. Still, it is quite remarkable that the local
consumption of FXIII-A in the cerebral venous system is
reﬂected in systemic FXIII-A levels. FXIII-A was also related
to the severity of CVT by an association between FXIII-A and
GCS, and patients with the most severe condition (GCS < 9)
had the lowest FXIII-A levels.
AP-FXIII levels were not associated with CVT. However,
we detected an inverse correlation of AP-FXIII with the
duration of symptoms. This may suggest that AP-FXIII has
a short half-life after its release into the circulation during
FXIII activation and it can mostly be detected at the time of
the acute event. In contrast, it takes much longer for the
consumed plasma FXIII to be replenished so that its reduc-
tion can still be measured in the subacute phase.
Diagnosis of CVT can be challenging, therefore novel
biomarkers may be helpful to improve and accelerate diag-
nosis. FXIII-A or AP-FXIII levels, however, are not relevant as
diagnostic markers for CVT since they do not allow the
Table 1 Characteristics of CVT and non-CVT patients
CVT
(n ¼ 94)
No CVT
(n ¼ 250)
p-Value
Age (y) 42.3 (14.8) 43.0 (16.8) n.s.
Gender, male vs.
female (%)
21:73 83:167 n.s.
(22:78%) (33:67%)
BMI (kg/m2) 26.4 (6.4) 25.6 (5.1) n.s.
Smoking 21 (23%) 91 (36%) 0.010
Hemostasis
disorders
9 (10%) 1 (0.4%) <0.001
Oral contraception 48 (66%) 36 (14%) <0.001
Malignoma 9 (10%) 10 (4%) 0.035
Symptom
duration (d)
8.2 (7.6) 6.6 (11.9) <0.001
GCS on admission 13.9 (2.2) 14.6 (1.5) <0.001
D-dimer (ng/mL) 3,322.0
(7,529.4)
999.1
(3,997.6)
<0.001
FXIII-A antigen (%) 93.2 (27.9) 107.6 (27.3) <0.001
AP-FXIII (ng/mL) 4.9 (3.7) 4.8 (4.1) n.s.
Abbreviations: BMI, body mass index; CVT, cerebral venous thrombosis;
GCS, Glasgow Coma Scale; n.s., not statistically signiﬁcant.
Note: Data shown as mean (standard deviation) or numbers (%).
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discrimination sufﬁciently between patients with and with-
out CVT.
In conclusion, our study conﬁrms the concept of activa-
tion and consumption of FXIII during acute thrombotic
events for the ﬁrst time in CVT. The changes in FXIII plasma
levels reﬂect the extent of clot formation and emphasize the
crucial contribution of FXIII to thrombus generation, but do
not represent a biomarker for the diagnosis of CVT.
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Table 2 Stratiﬁcation of non-CVT patients
CVT (n ¼ 94) Other vascular
diseases (n ¼ 31)
No CVT, no vascular
disease (n ¼ 219)
p-Value
FXIII-A antigen
(%)
93.2 (27.8) 102.5 (32.9) 108.3 (26.5) <0.001a
n.s.b,c
AP-FXIII
(ng/mL)
4.9 (3.7) 5.3 (7.4) 4.7 (3.4) n.s.a,b,c
D-dimer
(ng/mL)
3,322.0 (7,529.4) 2,932.1 (8,803.0) 725.5 (2,642.5) <0.001a,b,c
Abbreviation: CVT, cerebral venous thrombosis; n.s., not statistically signiﬁcant.
Note: Data shown as mean (standard deviation).
aCVT versus no CVT.
bCVT versus other vascular diseases.
cOther vascular diseases versus no CVT, no vascular disease.
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